proxyvotesnow.com

Home › Companies › APELLIS PHARMACEUTICALS INC. › 2024-2025

APELLIS PHARMACEUTICALS INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and APELLIS PHARMACEUTICALS INC.’s Form 8-K, filed 2025-06-04 (Item 5.07 on EDGAR). Page generated 02 October 2026.

  • 8Reported items
  • 254Asset managers
  • 1,997Fund votes
  • 2025-06-03Meeting date

Proxy season: 2023-2024 2024-2025

Explore APELLIS PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by APELLIS PHARMACEUTICALS INC.

These tallies are APELLIS PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-06-04 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

APELLIS PHARMACEUTICALS INC. — official shareholder meeting results, meeting held 2025-06-03
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Elect Director: A. Sinclair Dunlop 54,091,088---- 26,037,79523,918,223 Majority: yes
Elect Director: Alec Machiels 62,314,110---- 17,814,77423,918,223 Majority: yes
Elect Director: Keli Walbert 76,951,740---- 3,177,14423,918,223 Majority: yes
The stockholders of the Company ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025. 103,876,32654,603116,178 ---- Majority: yes
The stockholders of the Company approved the advisory vote on the compensation of the Company's named executive officers. 75,901,9204,167,10359,860 --23,918,223 Majority: yes

Source: APELLIS PHARMACEUTICALS INC., Form 8-K, filed with the SEC on 2025-06-04 — read the filing on EDGAR.

How asset managers voted at the APELLIS PHARMACEUTICALS INC. 2024-2025 meeting

Each item below shows how the 254 asset managers that disclosed a APELLIS PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of APELLIS PHARMACEUTICALS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To hold an advisory vote to approve the compensation paid to our named executive officers;

COMPENSATIONMajority of the votes cast: yes

Meeting held 2025-06-03.

Combines 9 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 75,901,920AGAINST: 4,167,103

APELLIS PHARMACEUTICALS INC.’s own tally for this item (“The stockholders of the Company approved the advisory vote on the compensation of the Company's named executive officers.”): 75,901,920 for, 4,167,103 against, per its Form 8-K filed 2025-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 125,661,000 outstanding shares: 60% for, 3% against (64% of the company cast a for/against vote).

The 251 asset managers below cast 96% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

FOR 96%
FOR: 95.7%AGAINST: 4.3%ABSTAIN: 0.0%NOT VOTED: 0.0%
Largest asset managers voting on “To hold an advisory vote to approve the compensation paid to our named executive officers;” at APELLIS PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard20,643,3562,837 00For
EcoR1 Capital, LLC11,895,8080 00For
Wellington11,883,3430 00For
State Street5,782,4066,682 00For
BlackRock5,208,6530 00For
Avoro Capital Advisors LLC4,944,5460 00For
Fidelity4,070,2450 00For
Siren, L.L.C.2,237,5110 00For
AQR2,169,3200 00For
JENNISON ASSOCIATES LLC2,061,8464,298 00For
GEODE CAPITAL MANAGEMENT, LLC1,955,2020 00For
Charles Schwab1,930,2600 00For
SUVRETTA CAPITAL MANAGEMENT, LLC01,835,131 00Against
Deep Track Capital, LP1,503,6300 00For
ORBIMED ADVISORS LLC1,432,3000 00For
Prudential/PGIM1,116,9610 00For
CANADA PENSION PLAN INVESTMENT BOARD1,050,7000 00For
Invesco978,0110 00For
BRAIDWELL LP916,8640 00For
Amundi0592,918 00Against
Nuveen0491,498 00Against
TIAA0482,718 00Against
Northern Trust481,4560 00For
Victory Capital423,1070 00For
Columbia Threadneedle403,9390 00For

Showing the 25 largest of 251 asset managers. See all 251 in the interactive database.

2. To hold an advisory vote on the frequency of future advisory votes on the compensation paid to our named executive officers; and

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2025-06-03.

Combines 5 wordings of this item as funds reported it.

97% fund support · no official result

ONE YEAR 57%1 YEAR 42%

The 240 asset managers below cast 97% of the shares they voted on this item FOR (96,909 for, 2,549 against).

FOR: 96,909 (0.1%)AGAINST: 2,549 (0.0%)ABSTAIN: 735 (0.0%)ONE YEAR: 46,702,654 (57.5%)1 YEAR: 34,326,399 (42.2%)3 YEARS: 144,419 (0.2%)NOT VOTED: 10,367 (0.0%)1-YEAR: 7,566 (0.0%)THREE YEARS: 99 (0.0%)1.0: 1 (0.0%)3 YEAR: 0 (0.0%)2 YEAR: 0 (0.0%)3.0: 0 (0.0%)2.0: 0 (0.0%)
Largest asset managers voting on “To hold an advisory vote on the frequency of future advisory votes on the compensation paid to our named execu” at APELLIS PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard00 00One Year
Wellington00 001 Year
State Street00 00One Year
BlackRock00 001 Year
Avoro Capital Advisors LLC00 001 Year
Fidelity00 00One Year
Siren, L.L.C.00 001 Year
AQR00 00One Year
JENNISON ASSOCIATES LLC00 001 Year
GEODE CAPITAL MANAGEMENT, LLC00 00One Year
Charles Schwab00 001 Year
SUVRETTA CAPITAL MANAGEMENT, LLC00 00One Year
Deep Track Capital, LP00 001 Year
ORBIMED ADVISORS LLC00 001 Year
Prudential/PGIM00 00One Year
CANADA PENSION PLAN INVESTMENT BOARD00 00One Year
Invesco00 00One Year
BRAIDWELL LP00 00One Year
Amundi00 00One Year
Nuveen00 00One Year
TIAA00 00One Year
Northern Trust00 001 Year
Victory Capital00 00One Year
Columbia Threadneedle00 00One Year
BALYASNY ASSET MANAGEMENT L.P.00 001 Year

Showing the 25 largest of 240 asset managers. See all 240 in the interactive database.

3. Election of three Class II directors to hold office until the 2028 Annual Meeting of Stockholders: A. Sinclair Dunlop

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-03.

Combines 5 wordings of this item as funds reported it.

68% Majority: yes · of votes cast

FOR 68%WITHHELD 32%
FOR: 54,091,088WITHHELD: 26,037,795

APELLIS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: A. Sinclair Dunlop”): 54,091,088 for, 26,037,795 withheld, per its Form 8-K filed 2025-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 125,661,000 outstanding shares: 43% for, 21% withheld (64% of the company cast a for/withheld vote).

The 59 asset managers below cast 100% of the shares they voted on this item FOR (28,665,899 for, 0 against).

FOR 88%12%
FOR: 28,665,899 (87.6%)ABSTAIN: 4,059,760 (12.4%)NOT VOTED: 740 (0.0%)
Largest asset managers voting on “Election of three Class II directors to hold office until the 2028 Annual Meeting of Stockholders: A. Sinclair” at APELLIS PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard20,436,5300 1,4680For
Fidelity2,671,9460 00For
State Street5,2400 2,161,6620Abstain
BlackRock2,038,6460 00For
Prudential/PGIM1,113,7910 00For
Charles Schwab962,5250 00For
TIAA482,7180 00For
Invesco00 460,7130Abstain
Columbia Threadneedle403,9390 00For
AQR00 287,7650Abstain
Hartford237,7060 00For
Victory Capital1,0220 198,7780Abstain
Exchange Place Advisors Trust00 138,5050Abstain
Lincoln Financial00 104,2020Abstain
Jackson National00 82,7330Abstain
Northwestern Mutual55,5330 24,1550For
MASTER INVESTMENT PORTFOLIO74,0500 00For
First Trust00 71,1390Abstain
SEI00 66,9370Abstain
Direxion Shares ETF Trust00 62,4740Abstain
Waddell & Reed00 55,4970Abstain
Voya00 45,9110Abstain
JPMorgan39,8210 00For
ProShares00 39,5280Abstain
DWS00 34,1270Abstain

Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.

4. Election of three Class II directors to hold office until the 2028 Annual Meeting of Stockholders: Alec Machiels

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-03.

Combines 5 wordings of this item as funds reported it.

78% Majority: yes · of votes cast

FOR 78%WITHHELD 22%
FOR: 62,314,110WITHHELD: 17,814,774

APELLIS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Alec Machiels”): 62,314,110 for, 17,814,774 withheld, per its Form 8-K filed 2025-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 125,661,000 outstanding shares: 49.6% for, 14% withheld (64% of the company cast a for/withheld vote).

The 59 asset managers below cast 100% of the shares they voted on this item FOR (29,574,063 for, 0 against).

FOR 90%10%
FOR: 29,574,063 (90.4%)ABSTAIN: 3,151,596 (9.6%)NOT VOTED: 740 (0.0%)
Largest asset managers voting on “Election of three Class II directors to hold office until the 2028 Annual Meeting of Stockholders: Alec Machie” at APELLIS PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard20,437,9960 20For
Fidelity1,741,9240 930,0220For
State Street2,166,8170 850For
BlackRock00 2,038,6460Abstain
Prudential/PGIM1,113,7910 00For
Charles Schwab962,5250 00For
TIAA482,7180 00For
Invesco460,7130 00For
Columbia Threadneedle403,9390 00For
AQR287,7650 00For
Hartford237,7060 00For
Victory Capital199,8000 00For
Exchange Place Advisors Trust138,5050 00For
Lincoln Financial104,2020 00For
Jackson National82,7330 00For
Northwestern Mutual79,6880 00For
MASTER INVESTMENT PORTFOLIO00 74,0500Abstain
First Trust71,1390 00For
SEI65,6700 1,2670For
Direxion Shares ETF Trust62,4740 00For
Waddell & Reed55,4970 00For
Voya45,9110 00For
JPMorgan39,8210 00For
ProShares39,5280 00For
DWS34,1270 00For

Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.

5. Election of three Class II directors to hold office until the 2028 Annual Meeting of Stockholders: Keli Walbert

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-03.

Combines 5 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 76,951,740WITHHELD: 3,177,144

APELLIS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Keli Walbert”): 76,951,740 for, 3,177,144 withheld, per its Form 8-K filed 2025-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 125,661,000 outstanding shares: 61% for, 3% withheld (64% of the company cast a for/withheld vote).

The 59 asset managers below cast 100% of the shares they voted on this item FOR (32,517,454 for, 0 against).

FOR 99.3%
FOR: 32,517,454 (99.4%)ABSTAIN: 208,205 (0.6%)NOT VOTED: 740 (0.0%)
Largest asset managers voting on “Election of three Class II directors to hold office until the 2028 Annual Meeting of Stockholders: Keli Walber” at APELLIS PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard20,436,5330 1,4650For
Fidelity2,671,9460 00For
State Street2,166,9020 00For
BlackRock2,038,6460 00For
Prudential/PGIM1,113,7910 00For
Charles Schwab962,5250 00For
TIAA482,7180 00For
Invesco460,7130 00For
Columbia Threadneedle403,9390 00For
AQR287,7650 00For
Hartford237,7060 00For
Victory Capital199,8000 00For
Exchange Place Advisors Trust138,5050 00For
Lincoln Financial00 104,2020Abstain
Jackson National82,7330 00For
Northwestern Mutual79,6880 00For
MASTER INVESTMENT PORTFOLIO74,0500 00For
First Trust71,1390 00For
SEI65,6700 1,2670For
Direxion Shares ETF Trust62,4740 00For
Waddell & Reed00 55,4970Abstain
Voya45,9110 00For
JPMorgan39,8210 00For
ProShares39,5280 00For
DWS34,1270 00For

Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.

6. Ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025;

AUDIT-RELATEDMajority of the votes cast: yes

Meeting held 2025-06-03.

Combines 4 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 103,876,326AGAINST: 54,603

APELLIS PHARMACEUTICALS INC.’s own tally for this item (“The stockholders of the Company ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.”): 103,876,326 for, 54,603 against, per its Form 8-K filed 2025-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 125,661,000 outstanding shares: 83% for, 0.1% against (83% of the company cast a for/against vote).

The 59 asset managers below cast 99.9% of the shares they voted on this item FOR (32,723,901 for, 1,023 against).

FOR 99.9%
FOR: 32,723,901 (100.0%)AGAINST: 1,023 (0.0%)ABSTAIN: 735 (0.0%)NOT VOTED: 740 (0.0%)
Largest asset managers voting on “Ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm ” at APELLIS PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard20,437,9980 00For
Fidelity2,671,9460 00For
State Street2,166,9020 00For
BlackRock2,038,6460 00For
Prudential/PGIM1,113,7910 00For
Charles Schwab962,5250 00For
TIAA482,7180 00For
Invesco460,7130 00For
Columbia Threadneedle403,9390 00For
AQR287,7650 00For
Hartford237,7060 00For
Victory Capital199,8000 00For
Exchange Place Advisors Trust138,5050 00For
Lincoln Financial104,2020 00For
Jackson National82,7330 00For
Northwestern Mutual79,6880 00For
MASTER INVESTMENT PORTFOLIO74,0500 00For
First Trust71,1390 00For
SEI66,9370 00For
Direxion Shares ETF Trust62,4740 00For
Waddell & Reed55,4970 00For
Voya45,9110 00For
JPMorgan39,8210 00For
ProShares39,5280 00For
DWS34,1270 00For

Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.

7. Advisory Vote on Say on Pay Frequency

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2025-06-03.

— fund support · no official result

1 YEAR 57%ONE YEAR 43%

No shares were cast for or against this item by the managers below — every disclosed position was an abstention or was not voted.

1 YEAR: 114,783 (57.3%)ONE YEAR: 85,622 (42.7%)
Largest asset managers voting on “Advisory Vote on Say on Pay Frequency” at APELLIS PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Granahan Investment Management, LLC00 001 Year
JPMorgan00 00One Year
EFG Asset Management (North America) Corp.00 00One Year
GuideStone00 00One Year
HC CAPITAL TRUST00 00One Year

8. Approval of an advisory vote on executive compensation.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Meeting held 2024-06-05 (outside the 2024-2025 season's 1 July to 30 June window; reported in this season's filings).

Combines 3 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%10%
FOR: 93,573,357AGAINST: 10,540,010

APELLIS PHARMACEUTICALS INC.’s own tally for this item (“The stockholders of the Company approved the advisory vote on the compensation of the Company's named executive officers.”): 93,573,357 for, 10,540,010 against, per its Form 8-K filed 2024-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 125,661,000 outstanding shares: 74% for, 8% against (83% of the company cast a for/against vote).

The 3 asset managers below cast 99.2% of the shares they voted on this item FOR (91,901 for, 687 against).

FOR 99.2%
FOR: 91,901 (99.3%)AGAINST: 687 (0.7%)
Largest asset managers voting on “Approval of an advisory vote on executive compensation.” at APELLIS PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Brighthouse91,9010 00For
COLDSTREAM CAPITAL MANAGEMENT INC0687 00Against
Echo45 Advisors LLC00 00--

Largest APELLIS PHARMACEUTICALS INC. shareholders voting in 2024-2025

Ranked by the number of APELLIS PHARMACEUTICALS INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 125,661,000 shares outstanding at the time of that meeting.

Top APELLIS PHARMACEUTICALS INC. shareholders by shares voted, 2024-2025
#Asset manager % of shares outstanding
1Vanguard 16.43%
2EcoR1 Capital, LLC 9.47%
3Wellington 9.46%
4State Street 4.61%
5BlackRock 4.15%
6Avoro Capital Advisors LLC 3.93%
7Fidelity 3.24%
8Siren, L.L.C. 1.78%
9AQR 1.73%
10JENNISON ASSOCIATES LLC 1.64%

Reported APELLIS PHARMACEUTICALS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

APELLIS PHARMACEUTICALS INC. beneficial owners on record for the 2024-2025 proxy season
Holder % outstanding Disclosure
Wellington Management 9.79% 13F
Vanguard Group 8.06% 13F
Morgan Stanley 7.66% 13F
BlackRock 5.04% 13F
Deep Track Capital, LP 3.61% 13G
State Street 3.14% 13F
RTW Investments, LP 2.93% 13G
Geode Capital 1.55% 13F
FMR (Fidelity) 1.20% 13F
Norges Bank 0.80% 13F

Percentages above are of 125,661,000 shares outstanding, as reported by APELLIS PHARMACEUTICALS INC. on its Form 10-Q dated 2025-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from APELLIS PHARMACEUTICALS INC.’s 10-Q dated 2025-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At APELLIS PHARMACEUTICALS INC.'s shareholder meeting held 2025-06-03, in the 2024-2025 proxy season, 254 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,997 separate fund positions. Their filings are grouped here into 8 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To hold an advisory vote to approve the compensation paid to our named executive officers; — FOR was 95% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: APELLIS PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-06-04.

APELLIS PHARMACEUTICALS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page).